Clinically approved PI3K and mTOR inhibitors, such as Buparlisib, Pictilisib, and Alpelisib, are used for treating cancers, and more inhibitors targeting AKT and dual PI3K/mTOR inhibitors are under clinical trials [33]. The gene discussed is AKT1; the disease is cancer.